Form 4: Recursion Pharmaceuticals Director Trades 30,000 Shares
Statement of Changes in Beneficial Ownership
Blake Borgeson, a Director at Recursion Pharmaceuticals, Inc., reported a transaction involving 30,000 shares of Class A Common Stock on April 7, 2026, executed under a Rule 10b5-1 trading plan.
Summary
- Director Blake Borgeson of Recursion Pharmaceuticals, Inc. (RXRX) sold 30,000 shares of Class A Common Stock on April 7, 2026.
- The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 31, 2025.
- The sale price was $3.10 per share.
- Following this transaction, Borgeson beneficially owns 6,229,863 shares of Class A Common Stock directly.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the sale of a significant number of shares by a director, despite the transaction being executed under a pre-established 10b5-1 plan.
Negatives
- Director Blake Borgeson sold a significant number of shares (30,000) of Class A Common Stock.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that insider selling, even under a Rule 10b5-1 plan, can sometimes be interpreted by the market as a signal of reduced confidence, although the plan's existence aims to mitigate this perception by demonstrating pre-planned, non-opportunistic trading.
Stakeholder Impact
- Shareholders may view the sale of shares by a director with caution, potentially impacting short-term stock sentiment, even though it was conducted under a pre-arranged plan.
Key Dates
| Date | Description |
|---|---|
| 2025-08-31 | Date Rule 10b5-1 trading plan was adopted by Reporting Person. |
| 2026-04-07 | Transaction Date for the sale of Class A Common Stock. |
| 2026-04-08 | Date the Form 4 was signed by attorney-in-fact. |
Recommendation
holdThe filing reports a sale of shares by a director under a Rule 10b5-1 plan. While insider selling can be a negative signal, the pre-planned nature of the transaction suggests it may not reflect a current negative view of the company's prospects. Without additional context on the company's performance or future outlook, a 'hold' recommendation is prudent, allowing for further analysis of the company's fundamentals.
Keywords
Form 4, Insider Trading, SEC Filing, Recursion Pharmaceuticals, RXRX, Blake Borgeson, Stock Sale, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.